A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses

Clinical Therapeutics

Volumn 32, Issue 13, 2010, Pages 2186-2197

  Beran, Jiri ^a   Abdel Messih, Ibrahim A ^b   Raupachova, Jolana ^a   Hobzova, Lenka ^a   Fragapane, Elena ^b  

^a Vaccination and Travel Medicine Centre   (Czech Republic)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

Adjuvant; H5N1; Heterologous immunity; Influenza; MF59; Prepandemic

Indexed keywords

INFLUENZA VACCINE;

ABDOMINAL PAIN; ADULT; ARTICLE; BACKACHE; CZECH REPUBLIC; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; DRUG TOLERABILITY; DYSMENORRHEA; DYSPEPSIA; ERYTHEMA; FATIGUE; FEMALE; FEVER; GASTROENTERITIS; HEADACHE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; OPEN STUDY; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SEROCONVERSION; SUBDURAL HEMATOMA; UPPER RESPIRATORY TRACT INFECTION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMAGGLUTINATION; HEMAGGLUTINATION INHIBITION TESTS; HEMOLYSIS; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; POLYSORBATES; SQUALENE; YOUNG ADULT;

EID: 79951527599     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(11)00024-5     Document Type: Article

References (33)

1. Chen H, Smith GJ, Li KS, et al. Establishment of multiple sublineages of H5N1 influenza virus in Asia: Implications for pandemic control. Proc Natl Acad Sci U S A 2006, 103:2845-2850.
2. Mounier-Jack S, Coker RJ How prepared is Europe for pandemic influenza? Analysis of national plans. Lancet 2006, 367:1405-1411.
3. Poland GA Vaccines against avian influenza-a race against time. N Engl J Med. 2006, 354:1411-1413.
4. Sambhara S, Poland GA Avian influenza vaccines: What's all the flap?. Lancet 2006, 367:1636-1638.
5. Shortridge KF Influenza pandemic preparedness: Gauging from EU plans. Lancet 2006, 367:1374-1375.
6. Stephenson I, Gust I, Kieny MP, Pervikov Y Development and evaluation of influenza pandemic vaccines. Lancet Infect Dis. 2006, 6:71-72.
7. Tiensin T, Chaitaweesub P, Songserm T, et al. Highly pathogenic avian influenza H5N1, Thailand, 2004. Emerg Infect Dis. 2005, 11:1664-1672.
8. Tran TH, Nguyen TL, Nguyen TD, et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med. 2004, 350:1179-1788. World Health Organization International Avian Influenza Investigative Team.
9. Ungchusak K, Auewarakul P, Dowell SF, et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med. 2005, 352:333-340.
10. Webster RG, Govorkova EA H5N1 influenza-continuing evolution and spread. N Engl J Med. 2006, 355:2174-2177.
11. Wood JM Selection of influenza vaccine strains and developing pandemic vaccines. Vaccine 2002, 20(Suppl 5):B40-B44.
12. Ferguson NM, Cummings DA, Fraser C, et al. Strategies for mitigating an influenza pandemic. Nature 2006, 442:448-452.
13. Note for guidance on harmonization of requirements for influenza vaccines March 12, 1997, European Agency for the Evaluation of Medicinal Products, Accessed December 9, 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003815.pdf.
14. Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenzaA/Duck/Singapore/97 (H5N3) vaccine: A randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001, 357:1937-1943.
15. Banzhoff A, Gasparini R, Laghi-Pasini F, et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults [published correction appears in PLoS ONE. 2009. doi: 10.1371/annotation/5f2ae0fb-48c2-aa19-9114765ba029]. PLoS ONE 2009, 4:e4384.
16. Galli G, Hancock K, Hoschler K, et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci U S A 2009, 106:7962-7967.
17. Leroux-Roels I, Van der Wielen M, Kafeja F, et al. Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults. Vaccine 2009, 27:6918-6925.
18. Bernstein DI, Edwards KM, Dekker CL, et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis. 2008, 197:667-675.
19. Bresson JL, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: Phase I randomised trial. Lancet 2006, 367:1657-1664.
20. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: A randomised controlled trial. Lancet 2007, 370:580-589.
21. Podda A, Del Giudice G MF59-adjuvanted vaccines: Increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2003, 2:197-203.
22. Stephenson I, Bugarini R, Nicholson KG, et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A potential priming strategy. J Infect Dis. 2005, 191:1210-1215.
23. O'Hagan DT MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 2007, 6:699-710.
24. Atmar RL, Keitel WA, Patel SM, et al. Safety and immunogenicity of non-adjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis. 2006, 43:1135-1142.
25. Vesikari T, Pellegrini M, Karvonen A, et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J. 2009, 28:563-571.
26. Stephenson I, Nicholson KG, Wood JM, et al. Confronting the avian influenza threat: Vaccine development for a potential pandemic. Lancet Infect Dis. 2004, 4:499-509.
27. Schild GC, Pereira MS, Chakraverty P Single-radial-hemolysis: A new method for the assay of antibody to influenza haemagglutinin. Applications for diagnosis and seroepidemiologic surveillance of influenza. Bull World Health Organ 1975, 52:43-50.
28. Confirmed human cases of avian influenza A (H5N1). Epidemic and pandemic alert and response 2007, World Health Organization (WHO), Accessed December 8, 2010. http://www.who.int/csr/disease/avian_influenza/country/en/.
29. Schultze V, D'Agosto V, Wack A, et al. Safety of MF59 adjuvant. Vaccine 2008, 26:3209-3222.
30. Vesikari T, Groth N, Karvonen A, et al. MF59-adjuvanted influenza vaccine (FLUAD) in children: Safety and immunogenicity following a second year seasonal vaccination. Vaccine 2009, 27:6291-6295.
31. Galli G, Medini D, Borgogni E, et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A 2009, 106:3877-3882.
32. Stephenson I, Nicholson KG, Hoschler K, et al. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med. 2008, 359:1631-1633.
33. Podda A The adjuvanted influenza vaccines with novel adjuvants: Experience with the MF59-adjuvanted vaccine. Vaccine 2001, 19:2673-2680.